toxicity

Conference Coverage

Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL

12/09/2020

Journal of Clinical Pathways

Videos

HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM

12/08/2020

Journal of Clinical Pathways

Feature

Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond

03/23/2017

Sandeep Parsad , PharmD, BCOP;

Chadi Nabhan , MD, MBA, FACP;

Bruce A. Feinberg , DO;

Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...

...

03/23/2017

Journal of Clinical Pathways

Research in Review

Drug Combinations Cost-Effective for Reducing Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma

03/08/2016

JCP Editors

A study comparing seven prophylaxis strategies for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma receiving chemotherapy found that routine primary prophylaxis (PP) with...

...

03/08/2016

Journal of Clinical Pathways